Glofitamab (RO7082859) is a bispecific antibody designed for targeted cancer immunotherapy, featuring a unique 2:1 architecture that incorporates dual binding sites for CD20 on B cells and a single binding site for CD3 on T cells. This configuration facilitates the selective engagement and activation of T cells, which then proliferate and exert cytotoxic effects on malignant cells expressing CD20. Clinically, Glofitamab has demonstrated the capacity to induce durable complete remissions in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (B-NHL), highlighting its potential as a therapeutic agent in hematologic oncology.
Glofitamab (RO7082859) is a bispecific antibody designed for targeted cancer immunotherapy, featuring a unique 2:1 architecture that incorporates dual binding sites for CD20 on B cells and a single binding site for CD3 on T cells. This configuration facilitates the selective engagement and activation of T cells, which then proliferate and exert cytotoxic effects on malignant cells expressing CD20. Clinically, Glofitamab has demonstrated the capacity to induce durable complete remissions in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (B-NHL), highlighting its potential as a therapeutic agent in hematologic oncology.
This calculator helps you calculate mass of compound based on solution concentration, volume and molecular weight in a specific solution using the formula:
